FTSE All-Share
5.566,13
PKT
+32,53
PKT
+0,59
%
Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Werbung
Analysen zu FTSE All-Share-Werten
| Datum | Rating | Analyst | |
|---|---|---|---|
| 02.04.26 | GSK Buy | Jefferies & Company Inc. | |
| 02.04.26 | Shell (ex Royal Dutch Shell) Buy | Jefferies & Company Inc. | |
| 02.04.26 | BP Hold | Jefferies & Company Inc. | |
| 02.04.26 | AstraZeneca Overweight | JP Morgan Chase & Co. | |
| 02.04.26 | Rio Tinto Hold | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
| 02.04.26 | Shell (ex Royal Dutch Shell) Buy | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
| 02.04.26 | BP Buy | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
| 02.04.26 | London Stock Exchange (LSE) Buy | Jefferies & Company Inc. | |
| 01.04.26 | HSBC Buy | Goldman Sachs Group Inc. | |
| 01.04.26 | Unilever Hold | Deutsche Bank AG | |
| 01.04.26 | Unilever Overweight | Barclays Capital | |
| 01.04.26 | National Grid Buy | Deutsche Bank AG | |
| 01.04.26 | Unilever Overweight | JP Morgan Chase & Co. | |
| 01.04.26 | Diageo Buy | Jefferies & Company Inc. | |
| 01.04.26 | Unilever Outperform | Bernstein Research | |
| 01.04.26 | Unilever Underperform | Jefferies & Company Inc. | |
| 01.04.26 | Diageo Overweight | Barclays Capital | |
| 01.04.26 | BP Overweight | Barclays Capital | |
| 01.04.26 | National Grid Overweight | JP Morgan Chase & Co. | |
| 31.03.26 | Unilever Outperform | Bernstein Research | |
| 31.03.26 | AstraZeneca Overweight | Barclays Capital | |
| 31.03.26 | AstraZeneca Overweight | JP Morgan Chase & Co. | |
| 31.03.26 | Unilever Underperform | Jefferies & Company Inc. | |
| 31.03.26 | Unilever Underperform | RBC Capital Markets | |
| 31.03.26 | AstraZeneca Buy | Jefferies & Company Inc. | |
| 31.03.26 | Unilever Overweight | JP Morgan Chase & Co. | |
| 31.03.26 | London Stock Exchange (LSE) Overweight | JP Morgan Chase & Co. | |
| 31.03.26 | Shell (ex Royal Dutch Shell) Overweight | Barclays Capital | |
| 31.03.26 | BP Overweight | Barclays Capital | |
| 31.03.26 | AstraZeneca Overweight | Barclays Capital | |
| 31.03.26 | GSK Underweight | Barclays Capital | |
| 31.03.26 | Diageo Buy | Deutsche Bank AG | |
| 31.03.26 | Diageo Buy | Deutsche Bank AG | |
| 30.03.26 | Rio Tinto Equal-weight | Morgan Stanley | |
| 30.03.26 | AstraZeneca Sell | Deutsche Bank AG | |
| 30.03.26 | GSK Underweight | JP Morgan Chase & Co. | |
| 30.03.26 | AstraZeneca Overweight | JP Morgan Chase & Co. | |
| 27.03.26 | AstraZeneca Overweight | Barclays Capital | |
| 27.03.26 | BAT Neutral | JP Morgan Chase & Co. | |
| 27.03.26 | AstraZeneca Buy | Jefferies & Company Inc. |